Meeting
2018 ASCO Annual Meeting
Phase 3 zanubrutinib (BGB‑3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Authors
Peter Hillmen
St. James's University Hospital, Leeds, United Kingdom
Peter Hillmen , Jennifer R. Brown , Brad S. Kahl , Paolo Ghia , Tadeusz Robak , Carol Marimpietri , Aileen Cohen , Jane Huang , Constantine Si Lun Tam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT03336333
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS7581)
DOI
10.1200/JCO.2018.36.15_suppl.TPS7581
Abstract #
TPS7581
Poster Bd #
218a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
First Author: Ömür Gökmen Sevindik
Poster
2023 ASCO Annual Meeting
Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
First Author: Doris K. Hansen
Poster
2023 ASCO Annual Meeting
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
First Author: Christopher Flowers
Poster
2023 ASCO Annual Meeting
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
First Author: Ian W. Flinn